Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
Summit and Nuvalent have scored prized plenary spots.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Inclacumab fails, and osivelotor is on hold.
J&J, Astra, Pfizer and others move yet more ADCs into human studies.
Shortly after ponsegromab, visugromab is to start phase 2/3.
Progress with three bispecific molecules is rewarded with a $120m equity raise.
